DRUG REPOSITIONING. Developing new therapeutic agents ("de novo") for human diseases is an increasingly lengthy and costly process, aimed at ensuring patient safety and drug efficacy. An alternative approach, drug repurposing or repositioning, involves using already commercialized or advanced molecules. This strategy offers several advantages, including the availability of extensive data on their safety, efficacy, and potential side effects. Drug repurposing speeds up the early drug development phases and prioritizes molecules for which the outcome on humans is documented. Drug repurposing currently benefits from methodological developments, such as better-annotated databases, the application of advanced algorithms and architectures in the field of AI, and novel physics-based modeling approaches. How is drug repurposing defined, and how much does it impact current drug development pipelines?